Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Priming with Idarubicin and Cytarabine in Relapsed/Refractory AML
NCT01607645Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Morphologic Complete Remission Rate at 3 months. Started Jul 2012; status: terminated.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01607645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01607645.